Literature DB >> 25380764

Identification of a novel MSH6 germline variant in a family with multiple gastro-intestinal malignancies by next generation sequencing.

Ashton A Connor1, Hagit Katzov-Eckert, Thomas Whelan, Melyssa Aronson, Lynette Lau, Christian Marshall, George S Charames, Aaron Pollett, Steven Gallinger, Jordan Lerner-Ellis.   

Abstract

The identification of germline variants that predispose to cancer is important to further our understanding of tumorigenesis, guide patient management, prevent disease in unaffected relatives, and inform best practice for health care. We describe a kindred with multiple gastrointestinal malignancies where a novel MSH6 germline susceptibility variant was identified by exome sequencing after eluding serial routine testing in multiple affected members. This case fosters discussion of our current understanding of DNA mismatch repair deficiency, the management of Lynch Syndrome, and the emerging role of next generation sequencing in laboratory medicine to identify rare pathogenic germline variants in a comprehensive, unbiased fashion.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25380764     DOI: 10.1007/s10689-014-9765-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  32 in total

1.  Determining the frequency of de novo germline mutations in DNA mismatch repair genes.

Authors:  Aung Ko Win; Mark A Jenkins; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Graham G Giles; Jack Goldblatt; Barbara A Leggett; John L Hopper; Stephen N Thibodeau; Noralane M Lindor
Journal:  J Med Genet       Date:  2011-06-02       Impact factor: 6.318

2.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

3.  Next-generation sequencing for clinical diagnostics.

Authors:  Howard J Jacob
Journal:  N Engl J Med       Date:  2013-10-02       Impact factor: 91.245

4.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.

Authors:  Jennifer J Johnston; Wendy S Rubinstein; Flavia M Facio; David Ng; Larry N Singh; Jamie K Teer; James C Mullikin; Leslie G Biesecker
Journal:  Am J Hum Genet       Date:  2012-06-14       Impact factor: 11.025

5.  Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.

Authors:  Daniel C Link; Laura G Schuettpelz; Dong Shen; Jinling Wang; Matthew J Walter; Shashikant Kulkarni; Jacqueline E Payton; Jennifer Ivanovich; Paul J Goodfellow; Michelle Le Beau; Daniel C Koboldt; David J Dooling; Robert S Fulton; R Hugh F Bender; Lucinda L Fulton; Kimberly D Delehaunty; Catrina C Fronick; Elizabeth L Appelbaum; Heather Schmidt; Rachel Abbott; Michelle O'Laughlin; Ken Chen; Michael D McLellan; Nobish Varghese; Rakesh Nagarajan; Sharon Heath; Timothy A Graubert; Li Ding; Timothy J Ley; Gerard P Zambetti; Richard K Wilson; Elaine R Mardis
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

6.  ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.

Authors:  Colin C Pritchard; Christina Smith; Stephen J Salipante; Ming K Lee; Anne M Thornton; Alex S Nord; Cassandra Gulden; Sonia S Kupfer; Elizabeth M Swisher; Robin L Bennett; Akiva P Novetsky; Gail P Jarvik; Olufunmilayo I Olopade; Paul J Goodfellow; Mary-Claire King; Jonathan F Tait; Tom Walsh
Journal:  J Mol Diagn       Date:  2012-05-30       Impact factor: 5.568

7.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

Review 8.  Disease-targeted sequencing: a cornerstone in the clinic.

Authors:  Heidi L Rehm
Journal:  Nat Rev Genet       Date:  2013-03-12       Impact factor: 53.242

9.  The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.

Authors:  Patrice Watson; Hans F A Vasen; Jukka-Pekka Mecklin; Inge Bernstein; Markku Aarnio; Heikki J Järvinen; Torben Myrhøj; Lone Sunde; Juul T Wijnen; Henry T Lynch
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

10.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.

Authors:  Jinru Shia
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.